-JCR Pharmaceuticals Co., Ltd., a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, has achieved a key research milestone in collaboration with Alexion, AstraZeneca Rare Disease (“Alexion”), focused on applying JCR’s proprietary J-Brain Cargo^® technology to develop a therapeutic protein candidate for a neurodegenerative disease. The achievement triggers a milestone payment from Alexion to JCR.

JCR and Alexion are advancing additional initiatives aimed at addressing areas of significant unmet medical need, including a December 2023 agreement to explore oligonucleotide therapeutics with J-Brain Cargo^® and a July 2025 license agreement to develop genomic medicines utilizing JCR’s JUST-AAV platform.

This milestone and the related payment have already been factored into JCR’s earnings forecast for the fiscal year ending March 31, 2026.